EUVIMEDObjevte EUVIMED
EUVIMED · CrossrefJournal

Lung Cancer

ISSN 0169-5002 · Elsevier BV

Latest articles

  1. Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum–etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational study (G-GUARD; TORG-TG2504)

    Shuhei Teranishi, Yuki Misumi, Takuma Ishihara, Yuta Yamanaka, Daiki Murata, Tomofumi Hirose, Ryosuke Ochiai, Kento Takagi, Yuko Higashi, Yusuke Hamakawa, Satoshi Ikeda, Naoki Furuya, Yoshiro Nakahara, Satoru Miura, Katsuhiko Naoki

    Published: 2026-12DOI: 10.1016/j.lungcan.2026.109671

  2. Coexistence of Osimertinib-Resistant and Osimertinib-Sensitive cell states in an EGFR-Mutant NSCLC model derived at osimertinib resistance

    Ilaria C. Chillico, Mariateresa Frascino, Giorgia Protopapa, Francesca Ruzzi, Elena Nironi, Francesca Giunchi, Damiano Pistone, Elisa Gruppioni, Annalisa Altimari, Marzia Rossato, Giacomo Lora, Francesco Agustoni, Mattia Lauriola, Andrea Ardizzoni, Patrick L.S. Michel, Sofia Fini, Pier-Luigi Lollini, Stefania Angelicola, Francesco Gelsomino, Arianna Palladini

    Published: 2026-12DOI: 10.1016/j.lungcan.2026.109680

  3. Characteristics and outcomes of patients with advanced or metastatic non–small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database

    Xiuning Le, Christos Chouaid, Fernando Lopez-Rios, Mei Sheng Duh, Maral DerSarkissian, Vadim Bernard-Gauthier, Jihong Zong, Zdravko Vassilev, Orsolya Lunacsek, Angela Lax, Andreas Schlicker, Rose Chang, Megan Pinaire, Naiyu Chen, Qayyim Said

    Published: 2026-11DOI: 10.1016/j.lungcan.2026.109677

  4. Navitoclax overcomes epithelial–mesenchymal transition-associated resistance in ALK-positive non-small cell lung cancer with rapid disease progression during alectinib treatment

    Tomoka Nishimura, Shuta Tomida, Tadahiro Kuribayashi, Takaaki Tanaka, Taku Noumi, Masataka Taoka, Shunta Mori, Jun Nishimura, Ayako Morita, Kenji Takada, Naofumi Hara, Hiromi Watanabe, Kiichiro Ninomiya, Hisao Higo, Toshio Kubo, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Yoshinobu Maeda, Yosuke Togashi, Go Makimoto

    Published: 2026-11DOI: 10.1016/j.lungcan.2026.109681

Volumes

2026 · 6162025 · 6552024 · 4692023 · 4612022 · 4232021 · 5462020 · 6062019 · 5932018 · 5662017 · 4682016 · 4592015 · 4782014 · 5142013 · 6592012 · 6132011 · 5472010 · 4242009 · 6102008 · 3592007 · 4502006 · 5072005 · 1,8052004 · 3572003 · 1,5272002 · 3012001 · 2962000 · 1,0641999 · 2381998 · 2781997 · 1,3171996 · 8281995 · 1,2111994 · 1,5951993 · 5491992 · 2701991 · 1,1451990 · 3311989 · 4661988 · 511987 · 387

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.